14 May 2025
💊FDA's Patent Extension Determination for OMVOH
Determination of Regulatory Review Period for Purposes of Patent Extension; OMVOH
Summary
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OMVOH and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.
Agencies
- Health and Human Services Department
- Food and Drug Administration
Business Impact
$$$ - High
The regulatory determination on the review period for OMVOH affects patent extension, which can significantly impact financial outcomes for businesses involved in pharmaceutical development. Business owners and executives must prepare for compliance and potential petitioning related to patent durations.